The regulation of liver fibrosis by immune cells
-
摘要: 肝脏纤维化发病机制目前尚未完全明确,近年研究发现非特异性免疫和特异性免疫细胞均可对肝脏星状细胞产生调节作用,这些研究结果表明肝脏内各种免疫细胞的调节最终会影响肝脏疾病的进程,在肝纤维化的不同阶段发挥重要的作用,而肝星状细胞反过来也为免疫细胞的募集、激活创造了良好的微环境条件。Abstract: Pathogenesis of liver fibrosis is not yet entirely clear.Recent research found that innate and adaptive immune cells can initiate liver fibrosis by regulating hepatic stellate cells.These findings suggest that a variety of immune cells in the liver will eventually affect the progression of liver disease, and play vital role in different stages of liver fibrosis.In turn, hepatic stellate cells support a favorable micro-environmental conditions for immune cells recruitment and activation.
-
Key words:
- liver cirrhosis /
- immunity /
- hepatic stellate cell
-
[1]Muhanna N, Abu TL, Doron S, et al.Amelioration of hepaticfibrosis by NK cell activation[J].Gut, 2011, 60 (1) :90-98. [2]Karlmark KR, Wasmuth HE, Trautwein C, et al.Chemokine-directed immune cell infiltration in acute and chronic liverdisease[J].Expert Rev Gastroenterol Hepatol, 2008, 2 (2) :233-242. [3]Notas G, Kisseleva T, Brenner D.NK and NKT cells in liverinjury and fibrosis[J].Clin Immunol, 2009, 130 (1) :16-26. [4]Holt AP, Salmon M, Buckley CD, et al.Immune interactionsin hepatic fibrosis[J].Clin Liver Dis, 2008, 12 (4) :861-882, x. [5]Gao B, Jeong WI, Tian Z.Liver:An organ with predominantinnate immunity[J].Hepatology, 2008, 47 (2) :729-736. [6]Kolios G, Valatas V, Kouroumalis E.Role of Kupffer cells inthe pathogenesis of liver disease[J].World J Gastroenterol, 2006, 12 (46) :7413-20. [7]Friedman SL.Evolving challenges in hepatic fibrosis[J].NatRev Gastroenterol Hepatol, 2010, 7 (8) :425-36. [8]Wynn TA, Barron L.Macrophages:master regulators of in-flammation and fibrosis[J].Semin Liver Dis, 2010, 30 (3) :245-257. [9]Kapur NK.Transforming growth factor-beta:governing thetransition from inflammation to fibrosis in heart failure withpreserved left ventricular function[J].Circ Heart Fail, 2011, 4 (1) :5-7. [10]Henderson NC, Iredale JP.Liver fibrosis:cellular mecha-nisms of progression and resolution[J].Clin Sci (Lond) , 2007, 112 (5) :265-280. [11]Nakano H, Miyamura M, Kawasaki T, et al.Lymphocyte-mediated enhancement of hepatic fibrosis in chronic activehepatitis[J].Gastroenterol Jpn, 1985, 20 (1) :14-19. [12]Chiaramonte MG, Donaldson DD, Cheever AW, et al.An IL-13 inhibitor blocks the development of hepatic fibrosis dur-ing a T-helper type 2-dominated inflammatory response[J].J Clin Invest, 1999, 104 (6) :777-785. [13]Tang JT, Fang JY, Gu WQ, et al.T cell immune response iscorrelated with fibrosis and inflammatory activity in hepatitisB cirrhotics[J].World J Gastroenterol, 2006, 12 (19) :3015-3019. [14]Zheng MH, Gu DN, Braddock M, et al.CD4+CD25+reg-ulatory T cells:a therapeutic target for liver diseases[J].Ex-pert Opin Ther Targets, 2008, 12 (3) :313-326. [15]Rallon NI, Barreiro P, Soriano V, et al.Elevated TGF-beta1levels might protect HCV/HIV-coinfected patients from liv-er fibrosis[J].Eur J Clin Invest, 2011, 41 (1) :70-76. [16]Bhogal RK, Bona CA.B cells:no longer bystanders in liverfibrosis[J].J Clin Invest, 2005, 115 (11) :2962-2965. [17]Berres ML, Koenen RR, Rueland A, et al.Antagonism ofthe chemokine CCL5 ameliorates experimental liver fibrosisin mice[J].J Clin Invest, 2010, 120 (11) :4129-4140. [18]Tacke F, Zimmermann HW, Berres ML, et al.Serum che-mokine receptor CXCR3 ligands are associated with progres-sion, organ dysfunction and complications of chronic liverdiseases[J].Liver Int, 2011, 31 (6) :842-851. [19]Affo S, Bataller R.RANTES antagonism:A promising ap-proach to treat chronic liver diseases[J].J Hepatol, 2011, 55 (4) :936-938. [20]Tacke F, Luedde T, Trautwein C.Inflammatory pathways inliver homeostasis and liver injury[J].Clin Rev Allergy Immu-nol, 2009, 36 (1) :4-12.
本文二维码
计量
- 文章访问数: 3381
- HTML全文浏览量: 21
- PDF下载量: 784
- 被引次数: 0